BOS-589 / GSK, Boston Pharma - LARVOL DELTA

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs. (PubMed, Expert Opin Investig Drugs) - "Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed...Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment."

Journal • Review • Gastrointestinal Disorder • Inflammation

First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. (PubMed, Clin Pharmacol Drug Dev) - "Accumulation ratios for C , AUC , AUC , and AUC after twice-daily dosing to steady state ranged from 1.2 to 1.8 for all doses except the 200-mg dose, which had ratios between 1.9 and 2.7. Administration of GSK3352589 after SD and RD was well tolerated with no safety concerns in healthy subjects."

Clinical • Journal • P1 data • PK/PD data • RET

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - P2a; N=132; Completed; Sponsor: Boston Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion • Colorectal Cancer • Gastrointestinal Disorder • Immunology

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - P2a; N=132; Active, not recruiting; Sponsor: Boston Pharmaceuticals; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2020 ➔ May 2020; Trial primary completion date: Dec 2019 ➔ Apr 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) (clinicaltrials.gov) - P2a; N=132; Recruiting; Sponsor: Boston Pharmaceuticals

Clinical • New P2a trial